title: Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India.
abstract: BACKGROUND
  High risk HPV (HR-HPV) testing has been recommended as an effective tool along with cytology screening in identification of cervical intraepithelial lesions (CINs) and prevention of their progress towards invasive cervical cancer. The aim of this study was to assess the HR-HPV DNA status by Hybrid Capture 2 (HC2) assay in healthy asymptomatic women of North-East India.
  
  
  METHODS
  This study examined cervical cell samples of forty three (n=43) healthy women by HC2 assay. A High Risk HPV DNA kit (Qiagen) was used which can detect 13 high risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
  
  
  RESULTS
  The mean relative light units (RLU) for samples was in the range of 141-5, 94, 619. HR-HPV DNA was confirmed in 16% (7/43) of participant women samples. Among demographic and clinical parameters, menstrual irregularity (p=0.039) and infection history (p=0.028) has shown statistically significant differences between the HR-HPV-positive and negative groups. In the HR-HPV positive group, two women were confirmed for CINs after colposcopy and histopathologic examination.
  
  
  CONCLUSIONS
  We suggest that there may be an association between irregular menstruation and infection history of the urogenital tract with HR-HPV DNA prevalence in North-East Indian asymptomatic women. HC2 assay can be a valuable tool for HR-HPV screening.
authors.affiliation: DBT Centre for Molecular Biology and Cancer Research, Dr. B. Borooah Cancer Institute, Guwahati, India E-mail : dravdheshkumarrai@gmail.com.
authors.forename: Avdhesh Kumar
authors.initials: AK
authors.lastname: Rai
authors.forename: Debabrata
authors.initials: D
authors.lastname: Das
authors.forename: Amal Chandra
authors.initials: AC
authors.lastname: Kataki
authors.forename: Debabrata
authors.initials: D
authors.lastname: Barmon
authors.forename: Dippy
authors.initials: D
authors.lastname: Aggarwal
authors.forename: Pankaj
authors.initials: P
authors.lastname: Deka
authors.forename: Sushruta
authors.initials: S
authors.lastname: Shrivastava
authors.forename: Jagannath Dev
authors.initials: JD
authors.lastname: Sharma
authors.forename: Anupam
authors.initials: A
authors.lastname: Sarma
authors.forename: Upasana
authors.initials: U
authors.lastname: Baruah
authors.forename: Mousumi
authors.initials: M
authors.lastname: Sharma
mesh_terms: D000328:Adult; D000368:Aged; D002584:Cervix Uteri / Q000473:pathology*; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007194:India; D008875:Middle Aged; D009367:Neoplasm Staging; D027383:Papillomaviridae / Q000235:genetics* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis* / Q000821:virology; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011933:Reagent Kits, Diagnostic; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D014626:Vaginal Smears; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control
chemical_list: D004279:DNA, Viral; D011933:Reagent Kits, Diagnostic